A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vanzacaftor/tezacaftor/deutivacaftor triple combination ...
AbbVie is discontinuing all work in cystic fibrosis after a phase 2 flop, while also scrapping another phase 2 program in immunology. After analyzing data from a proof-of-concept study of the triple ...
Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated disease that differs from person to person. An autosomal recessive disorder ...
It is currently not possible to cure cystic fibrosis. However, medications and airway clearance techniques can help a person manage the condition. In severe cases, a doctor may recommend a lung ...
The United States Cystic Fibrosis Foundation released the first guideline on newborn screening for cystic fibrosis (CF), in order to improve timely detection of CF in infants from all racial and ...
Atypical cystic fibrosis is a mild form of cystic fibrosis. People with this type of cystic fibrosis can experience symptoms that come and go or that are less severe than those people with classic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results